Dr. Reddy's successfully completes Phase I study (IV route)

Dr. Reddy's Laboratories Ltd. , a global pharmaceutical company, announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study.

Related Keywords

United States , Reddy Tocilizumab , Tocilizumab Roactemra , Tocilizumab Actemra , Jayanth Sridhar , Reddy Laboratories , Reddy Laboratories Ltd , Double Blind , Comparative Pharmacokinetic , Pharmacodynamic Study , Reference Tocilizumab , Intravenous Route , Normal Healthy Male Volunteer , Global Head , Laboratories Limited , Drreddyslaboratories , Ine089a01023 , Ardy , Tocilizumab , Biosimilarcandidate , Phase1study ,